Skip to main content
Premium Trial:

Request an Annual Quote

Nalagenetics Gets CE Mark for PGx Software Module

NEW YORK — Singapore-based genetic testing software firm Nalagenetics said on Tuesday that it has received the CE mark for a reporting module for its flagship Clinical Decision Support (CDS) pharmacogenomics portal.

The module, called Nala CDS Module – PGx Core, is companion software for the company's research-use-only qPCR Nala PGx Core genotyping kit. The kit reads 20 variants within four genes — CYP2D6, CYP2C9, CYP2C19, and SLCO1B1 — and the software can generate over 170 drug-gene reports, Nalagenetics said.

"We are very excited about this milestone to build credibility in the European and home market in Southeast Asia," Nalagenetics CEO Levana Sani said in a statement. "With pharmacogenomics testing becoming more and more ubiquitous around the world, it requires standardized and robust tools to support the rapid increase of adoption."

In March, Nalagenetics closed a $12.6 million Series A financing round. About a month later, the firm partnered with MGI Tech to codevelop a low-coverage whole-genome sequencing workflow for risk prediction and pharmacogenomics.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.